-
van Barele M, Akdeniz D, Heemskerk-Gerritsen BAM, Andrieu N, et al.
Contralateral breast cancer risk in irradiated breast cancer patients with a
germline-BRCA1/2 pathogenic variant. J Natl Cancer Inst 2023.
-
Adimadhyam S, Lewis JD, Simon AL, Wolfe AE, et al.
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced
Patients With Ulcerative Colitis. Inflamm Bowel Dis 2023.
-
Tausch C, Daster K, Hayoz S, Matrai Z, et al.
Trends in use of neoadjuvant systemic therapy in patients with clinically
node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK
23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast Cancer Res Treat 2023.
-
Martin-Loeches I, Torres A, Nagavci B, Aliberti S, et al.
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired
pneumonia. Intensive Care Med 2023.
-
Hwang I, Kim JE, Jeong JH, Ahn JH, et al.
Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin
plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a
shorter treatment of three cycles of FEC followed by three cycles of docetaxel
(F Breast Cancer Res Treat 2023.
|